Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

TORONTO—NYU Langone Health has tapped Philips to help take its pathology program fully digital—including translating its ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

As it transitions from a discovery- to a clinical-stage biotech, Volastra Therapeutics is bringing longtime adviser Samuel ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company ...

Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing ...

Sanofi is putting down $18 million across three historically Black medical schools as part of the French pharma's efforts to boost clinical trial diversity.   | Big Pharma Sanofi is putting down $18 ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...